Mirum Pharmaceuticals, Inc. (MIRM) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated January 23, 2026, reports the completion of the acquisition of Bluejay Therapeutics, Inc. ("Bluejay") by Mirum Pharmaceuticals, Inc. The transaction was finalized on January 23, 2026, pursuant to a Merger Agreement dated December 6, 2025. Following the merger, Bluejay became a wholly-owned subsidiary of Mirum.
Key Financial Metrics and Transaction Details
- Acquisition Consideration:
- Upfront Consideration: Approximately $280.8 million in cash and 4,673,597 shares of Mirum common stock.
- Holdback Consideration: Up to $25.8 million in cash and 522,375 shares of Mirum common stock, subject to deliverables and holdbacks.
- Milestone Payments: Up to $200 million in cash contingent on achieving certain net sales milestones.
- Target Liquidity: Mirum acquired Bluejay's net cash of approximately $56.6 million.
- Capital Structure: Immediately following the merger and concurrent private placements, 59,879,958 shares of Mirum common stock were issued and outstanding.
- Related Financing: The Company closed two private placement offerings immediately following the consummation of the mergers.
Material Changes
The primary material change is the consolidation of Bluejay Therapeutics into Mirum Pharmaceuticals. All outstanding Bluejay capital stock and options were cancelled in exchange for the Merger Consideration. Entities affiliated with Frazier Life Sciences IX, L.P., which are beneficial owners of more than 5% of Mirum's stock, received their pro rata portion of the consideration.
Guidance, Outlook, and Risks
The filing does not provide specific forward-looking financial guidance or management commentary regarding future performance beyond the transaction terms. The potential for up to $200 million in milestone payments introduces contingent liabilities dependent on future net sales performance. The filing notes that financial statements of the acquired business and pro forma financial information will be filed in an amendment within 71 calendar days.
Investor Verification Checklist
- Verify the final cash outflow after accounting for the $56.6 million net cash acquired from Bluejay.
- Review the upcoming amendment to this Form 8-K for the required financial statements of Bluejay and pro forma financial information.
- Confirm the specific terms and conditions of the $200 million net sales milestones to assess the probability of future cash outflows.
- Examine the details of the concurrent private placement offerings to understand the dilution impact and capital raised.
- Review the full text of the Merger Agreement (Exhibit 2.1) for specific holdback conditions and tax deduction mechanisms.